However, similar therapeutics in AML thus far remain of limited utility as all leading targets (CD33, CD123, CLL-1) have significant expression on normal hematopoietic and/or endothelial cells, leading to “on target, off tumor” toxicity concerns5,6. This evidence concerns the gene CD33 and neoplasm.